Rampant Disease Osteoporosis: Under-diagnosed, Under-treated - Experts Call For Earlier Diagnosis And Therapy
"With a continuously ageing population the incidence of osteoporosis is steadily rising. This does not only pose problems to the individuals concerned but is also an enormous challenge for our societies" according to Professor Wolfhart Puhl, past president of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT). Prof. Puhl, of the Orthopç¤dikum Allgç¤u, Germany, who is in Vienna for the EFORT Congress, emphasized that the problem"s "dimension is frequently underestimated. Policy makers and funding agencies do not always consider this development sufficiently in their planning."
Health Insurance
Pages: 1 [2]
Denosumab Demonstrates Superiority Over Zometa(R) In Pivotal Phase 3 Head-to-Head Trial In Breast Cancer Patients With Bone Metastases
and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others" regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release. ZOMETA is a registered trademark of Novartis Oncology *Editors Note: The FDA has provisionally approved the trade name Prolia(TM) for the proposed indications of treatment and prevention of osteoporosis in postmenopausal women, and treatment and prevention of bone loss in patients undergoing hormone ablation for non-metastatic prostate or breast cancer, for which denosumab is administered twice yearly subcutaneously at a 60 mg dose. The Prolia(TM) trade name is only for these indications and may not apply for other indications of denosumab. References (1) Capanna R, Coia LR, Coleman R. et al. eds. Textbook of Bone Metastases. Hoboken, NJ: Edition: John Wiley and Sons; 2005:105. (2) Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002 Aug;2(8):584-93. (3) Schulman K and Kohles J. Cancer. 2007;109:2334-2342 (4) GVD/Barber ISPOR 2008 Poster; Schulman 2007; Delea et al. 2006 AmgenPages: 1 [2]